Novo Nordisk Faces Patent Expiry for Ozempic in India, China, and Other Countries

In Brief

Patent expirations may increase competition and lower costs for weight loss drugs in several major markets.

Key Facts

• Novo Nordisk is set to lose patent protection for Ozempic in India, China, and other nations.
• This change could allow for the introduction of cheaper generic versions of Ozempic.
• Novo Nordisk’s 7.2 mg dose of Wegovy was recently approved for use.
• A high dose of Wegovy helped people lose 21% of their weight, according to MarketWatch.
• Wegovy will compete with Lilly’s GLP-1 injection in the weight loss drug market.

What Happened

Novo Nordisk is nearing the end of its patent protection for Ozempic in India, China, and other countries, which may lead to generic alternatives. Meanwhile, the company’s higher-dose Wegovy has received approval and demonstrated significant weight loss results.

Why It Matters

The loss of patent protection could make weight loss drugs more affordable in populous countries, potentially impacting Novo Nordisk’s market share and pricing strategies. The approval of new doses and increased competition may influence treatment options for obesity.

What's Next

Generic versions of Ozempic may enter markets in India, China, and other nations. Competition among pharmaceutical companies is expected to intensify as new products and doses become available.